Exclusive: Women’s health biotech Freya Biosciences raises $38M for microbial immunotherapies

12 Dec 2023

Immunotherapy

Freya Biosciences, a Danish and US biotech named after the Norse goddess of fertility, has raised a $38 million Series A, the clinical-stage startup told Endpoints News exclusively. The Copenhagen and Boston startup, formed during the early days of the Covid-19 pandemic, will use the funding to test its investigational donor- and strain-derived microbial immunotherapies. “If we can shift the microbial ecology, we have that corresponding shift in the immune profile, which would then have an effect on these quite severe indications that are downstream of this inflammation that arises in the reproductive tract,” CEO Colleen Acosta said in an interview with Endpoints.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

FREYA

Indications

COVID-19Inflammation

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.